Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

HTAi Patient and Citizen Involvement. Good Practice Examples of Patient and Public Involvement in Health Technology Assessment. 2015. http://www.htai.org/fileadmin/HTAi_Files/ISG/PatientInvolvement/EffectiveInvolvement/Good_Practice_Examples_Feb_2015.pdf . Accessed 14 Aug 2017.

SMC. PACE—patient and clinician engagement. Factsheet. 2015. https://www.scottishmedicines.org.uk/files/PACE/PACE_factsheet_0417.pdf . Accessed 14 Aug 2017.

Shah KK, Mestre-Ferrandiz J, Towse A, Smyth EN. A review of health technology appraisals: case studies in oncology. Int J Technol Assess Health Care. 2013;29(1):101–9.

Devlin N, Sussex J. Incorporating multiple criteria in HTA: methods and processes. OHE Monograph. London: Office of Health Economics; 2011.

Danner M, Hummel JM, Volz F, van Manen JG, Wiegard B, Dintsios CM, et al. Integrating patients’ views into health technology assessment: analytic hierarchy process (AHP) as a method to elicit patient preferences. Int J Technol Assess Health Care. 2011;27(4):369–75.

Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making-an introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19(1):1–13.

Radaelli G, Lettieri E, Masella C, Merlino L, Strada A, Tringali M. Implementation of EUnetHTA core Model(R) in Lombardia: the VTS framework. Int J Technol Assess Health Care. 2014;30(1):105–12.

Castro H, Tringali M, Cleemput I, Devriese S, Leoni O, Lettieri E. Advancing MCDA and HTA into coverage decision-making. In: Marsh K, Goetghebeur M, Thokala P, Baltussen R, editors. Multi-criteria decision analysis to support healthcare decisions. Cham: Springer International Publishing; 2017. p. 119–46.

Wahlster P, Goetghebeur M, Schaller S, Kriza C, Kolominsky-Rabas P. Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study. Health Res Policy Syst. 2015;13:24.

Bentley TG, Cohen JT, Elkin EB, Huynh J, Mukherjea A, Neville TH, et al. Validity and reliability of value assessment frameworks for new cancer drugs. Value Health. 2017;20(2):200–5.

Wagner M, Khoury H, Willet J, Rindress D, Goetghebeur M. Can the EVIDEM framework tackle issues raised by evaluating treatments for rare diseases: analysis of issues and policies, and context-specific adaptation. Pharmacoeconomics. 2016;34(3):285–301.

Daniels N, Sabin JE. Accountability for reasonableness: an update. BMJ. 2008;337:a1850.

Tony M, Wagner M, Khoury H, Rindress D, Papastavros T, Oh P, et al. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada. BMC Health Serv Res. 2011;11:329.

Gilabert-Perramon A, Catalan A, Prat A, Fontanet M, Puig-Peiró R, Merino-Montero S, et al. Development of a multi-criteria decision analysis (MCDA) framework for health care decision-making in Catalonia (Spain): pilot study focused in orphan drugs. Vienna: ISPOR 19th Annual European Congress; 2016.

van Til J, Groothuis-Oudshoorn C, Lieferink M, Dolan J, Goetghebeur M. Does technique matter: a pilot study exploring weighting techniques for a multi-criteria decision support framework. Cost Eff Resour Alloc. 2014;12:22.

Sehn LH, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081–93.

European Medicines Agency. Assessment report Gazyvaro Procedure No. EMEA/H/C/002799/II/0007. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002799/WC500211313.pdf . Accessed 14 Aug 2017.

Lee L, Wang L, Crump M. Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin’s lymphoma: correlation of complete response, time-to-event and overall survival end points. Ann Oncol. 2011;22(6):1392–403.

Belton V, Pictet J. A framework for group decision using a MCDA model: sharing, aggregating or comparing individual information? J Decis Syst. 1997;6(3):283–303.

Claxton K. Three questions to ask when examining MCDA. Value Outcomes Spotlight. 2015;1:10–8.

Marsh K, IJmerzan M, Thokala P, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19(2):125–37.

Garau M, Devlin NJ. Using MCDA as a decision aid in health technology appraisal for coverage decisions: opportunities, challenges and unresolved questions. In: Marsh K, Goetghebeur M, Thokala P, Baltussen R, editors. Multi-criteria decision analysis to support healthcare decisions. Cham: Springer International Publishing; 2017. p. 277–98.

Golan O, Hansen P. Which health technologies should be funded? A prioritization framework based explicitly on value for money. Isr J Health Policy Res. 2012;1(1):44.

Sussex J, Towse A, Devlin N. Operationalizing value-based pricing of medicines: a taxonomy of approaches. Pharmacoeconomics. 2013;31(1):1–10.

Culyer A, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy. 2007;12(1):56–8.

Karlsberg Schaffer S, Sussex J, Devlin N, Walker A. Local health care expenditure plans and their opportunity costs. Health Policy. 2015;119(9):1237–44.

Appleby J, Devlin N, Parkin D, Buxton M, Chalkidou K. Searching for cost effectiveness thresholds in the NHS. Health Policy. 2009;91(3):239–45.

Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1–503 (v–vi).

Baltussen R. Question is not whether but how to use MCDA. Value Outcomes Spotlight. 2015;1(1):14–6.

Marsh K, Caro JJ, Hamed A, Zaiser E. Amplifying each patient’s voice: a systematic review of multi-criteria decision analyses involving patients. Appl Health Econ Health Policy. 2017;15(2):155–62.

Mühlbacher AC, Kaczynski A. Making good decisions in healthcare with multi-criteria decision analysis: the use, current research and future development of MCDA. Appl Health Econ Health Policy. 2016;14(1):29–40.

Phillips LD. Best Practice for MCDA in Healthcare. In: Marsh K, Goetghebeur M, Thokala P, Baltussen R, editors. Multi-criteria decision analysis to support healthcare decisions. Cham: Springer International Publishing; 2017. p. 311–29.

Golan O, Hansen P, Kaplan G, Tal O. Health technology prioritization: which criteria for prioritizing new technologies and what are their relative weights? Health Policy. 2011;102(2–3):126–35.